2 results match your criteria: "USA [2] University of Michigan Health System[Affiliation]"
Isavuconazole: A New Option for the Management of Invasive Fungal Infections.
Ann Pharmacother
July 2015
University of Michigan College of Pharmacy, Ann Arbor, MI, USA University of Michigan Health System, Ann Arbor, MI, USA
Objective: To review the pharmacology, chemistry, in vitro susceptibility, pharmacokinetics, clinical efficacy, safety, tolerability, dosage, and administration of isavuconazole, a triazole antifungal agent.
Data Sources: Studies and reviews were identified through an English language MEDLINE search (1978 to March 2015) and from http://www.clinicaltrials.
Incidence and Management of Rash in Telaprevir-Treated Patients.
Ann Pharmacother
September 2014
University of Michigan, Ann Arbor, MI, USA University of Michigan Health System, University Hospital, Ann Arbor, MI, USA.
Background: Telaprevir-induced rash is a common, therapy-limiting adverse drug event (ADE) for patients with hepatitis c virus (HCV) infection. Given the similarity between telaprevir and simeprevir, real-world management of rash during treatment with an NS3/4A protease inhibitor and its implications are important.
Objective: The objectives of this study were to determine the incidence of rash in telaprevir-treated patients, its management, and the impact on sustained virological response and to identify any risk factors for rash development.